A PYMNTS Company

India/US: Generic sale helps Teva-Allergan deal

By  |  July 27, 2016

India’s second-largest pharmaceutical company, Dr Reddy’s Laboratories Ltd, said it had agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash in an attempt to bolster its U.S. business.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The drugs Dr Reddy’s has agreed to buy are being divested by Israel-based Teva, in order to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan’s generic drugs portfolio. This sale to Dr Reddy’s puts Teva one step closer to closing the Allergan deal.

    The deal consists of some generic drugs awaiting U.S. approval, as well as some that are already on the market. The branded versions of drugs under the deal had U.S. sales of about $3.5 billion in the year leading to April 2016, the company reported citing healthcare research firm IMS Health.

    Full Content: NBC Daily

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.